Meeting
2015 ASCO Annual Meeting
Phase I study of safety and immunogenicity of ADU-623, a live-attenuated Listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRvIII and NY-ESO-1, in patients with WHO grade III/IV astrocytomas.
Authors
Marka Crittenden
Earle A. Chiles Research Institute, Portland, OR
Marka Crittenden , Keith S. Bahjat , Rui Li , Pankaj A. Gore , Chris Fountain , Bill Hanson , Justin Skoble , Peter Lauer , Aimee Murphy , Thomas Walter Dubensky Jr., Dirk G. Brockstedt , Walter John Urba
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Vaccines
Clinical Trial Registration Number
NCT01967758
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS3106)
DOI
10.1200/jco.2015.33.15_suppl.tps3106
Abstract #
TPS3106
Poster Bd #
422b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO).
First Author: Sandra P. D'Angelo
Poster
2019 ASCO Annual Meeting
Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM).
First Author: Sheeba K. Thomas
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I safety study of oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.
First Author: Boris Minev
Poster
2017 ASCO Annual Meeting
A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.
First Author: Chrisann Kyi